Post-Licensure Safety Study of ISENTRESS in a US Managed Care Network

Trial Profile

Post-Licensure Safety Study of ISENTRESS in a US Managed Care Network

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 06 Apr 2016 Number of groups changed from 3 to 7 in treatment table, Time frame for primary endpoint changed (January 2000 - December 2014 to Historical Cohort: up to 33 months (January 2005 to October 2007); Raltegravir and Concurrent Cohorts: up to 69 months (October 2007 to June 2013))
    • 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top